ANI Pharmaceuticals ANIP Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's fair value measurement disclosure?
- ANI Pharmaceuticals (ANIP) reported fair value measurement disclosure of $8.57M in Q1 2026.
- How has ANI Pharmaceuticals's fair value measurement disclosure changed year-over-year?
- ANI Pharmaceuticals's fair value measurement disclosure decreased by 26.5% year-over-year, from $11.66M to $8.57M.
- What is the long-term trend for ANI Pharmaceuticals's fair value measurement disclosure?
- Over 4 years (2021 to 2025), ANI Pharmaceuticals's fair value measurement disclosure has grown at a -28.0% compound annual growth rate (CAGR), from $31M to $8.35M.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.